表紙
市場調查報告書

癌症分子診斷市場 - 策略、趨勢,預測,包含COVID-19大流行造成的景氣衰退預測的:2021年∼2025年

Molecular Diagnostics for Cancer. Markets, Strategies and Trends. Forecasts by Cancer Type, including companion Dx and by Country. With Executive and Consultant Guides and COVID pandemic recession forecast revisions. 2021 to 2025

出版商 Howe Sound Research 商品編碼 970566
出版日期 內容資訊 英文 341 Pages
商品交期: 最快1-2個工作天內
價格
癌症分子診斷市場 - 策略、趨勢,預測,包含COVID-19大流行造成的景氣衰退預測的:2021年∼2025年 Molecular Diagnostics for Cancer. Markets, Strategies and Trends. Forecasts by Cancer Type, including companion Dx and by Country. With Executive and Consultant Guides and COVID pandemic recession forecast revisions. 2021 to 2025
出版日期: 2020年11月12日內容資訊: 英文 341 Pages
簡介

癌症的分子診斷,從基因組學知識的成長中直接受益。癌症的搭配診斷,是再形成產業的新市場區隔。

本報告提供全球癌症分子診斷市場相關調查分析,以130家以上的公司為對象,市場策略,趨勢,預測相關的系統性資訊。

目錄

第1章 簡介和市場定義

  • 所謂分子診斷
  • 診斷的革命
  • 市場定義
  • 調查手法
  • 美國的醫療市場與臨床檢驗 - 預測

第2章 市場概要

  • 市場參與企業
  • 市場區隔
  • 產業結構

第3章 市場趨勢

  • 成長促進因素
  • 成長阻礙因素
  • 儀器與自動化
  • 診斷技術的發展

第4章 分子診斷的最近開發

  • 最近的開發
  • 開發的重要性
  • 冠狀病毒的大流行深入歐洲的癌症研究
  • Veracyte的Prosigna ID患者
  • CRISPR和奈米孔洞定序的組合
  • 液態切片
  • Roche,Illumina
  • Saga,Sevier等

第5章 主要分子診斷 (MDx) 企業的簡介

  • 10x Genomics, Inc
  • Abbott Diagnostics
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medica
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asurage
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, In
  • Biodesix Inc.
  • BioFluidica
  • BioGene
  • Biolidics Lt
  • bioMerieux Diagnostics
  • Bioneer Corporatio
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomic
  • Bristol-Myers Squibb
  • Cancer Genetic
  • Caris Molecular Diagnostics
  • CellMax Lif
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynveni
  • Cytolumina Technologies Corp.
  • CytoTrac
  • Datar Cancer Genetics Limite
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Science
  • Epigenomics A
  • Eurofins Scientific
  • Exosome Diagnostic
  • Exosome Science
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenom
  • FUJIFILM Wako Diagnostics
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivat
  • Integrated Diagnostic
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigm
  • Miltenyi Biotec
  • MIOD
  • miR Scientifi
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyt
  • OncoDN
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologie
  • Panagene
  • Perkin Elme
  • Personal Genome Diagnostics
  • Personali
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SA
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sense Biodetection
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystem
  • simfo GmbH
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostic
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

第6章 全球癌症MDx市場

  • 癌症MDx - 全球市場概要:各國

第7章 全球癌症MDx市場 - 癌症的各類型

  • 全球市場:癌症的各類型 - 概要
    • 乳癌MDx
    • 大腸癌症MDx
    • 子宮頸癌症MDx
    • 肺癌症MDx
    • 前列腺MDx
    • 黑色素瘤MDx
    • 血液MDx
    • 搭配診斷MDx
    • 其他癌症MDx

第8章 癌症治療和臨床實驗

  • FDA的抗癌劑核准
  • 臨床實驗的開始
  • 癌症治療的盛行率

附錄

目錄

Report Overview:

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report from Howe Sound Research. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations. Trends like...

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • emergence of new economies with large markets
  • greater understanding of the role of genetic material in Disease and Health

Working against this dynamic market are the forces of the COVID Driven Recession. Our latest numbers factor in the different COVID forces and their timing. And their effect on growth.

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

In addition customization work, breakouts for particular segments, assistance and support is included free of charge with every report.

" Molecular Diagnostics for Cancer. Markets, Strategies and Trends. Forecasts by Cancer Type, including companion Dx and by Country. With Executive and Consultant Guides and COVID pandemic recession forecast revisions. 2021 to 2025" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i.Molecular Dx Oncology Market - Strategic Situation Analysis with Impact of the COVID Pandemic

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What is Molecular Diagnostics
  • 1.2 The Diagnostics Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 U.S. Medical Market and laboratory Testing - Perspective
    • 1.5.1 U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

  • 2.1 Market Participants
    • 2.1.1 Academic Research Lab
    • 2.1.2 Diagnostic Test Developer
    • 2.1.3 Genomic Instrumentation Supplier
    • 2.1.4 Pharmaceutical/Reagent Supplie
    • 2.1.5 Independent Testing La
    • 2.1.6 Public National/regional lab
    • 2.1.7 Hospital lab
    • 2.1.8 Physician Lab
    • 2.1.9 Audit Body
    • 2.1.10 Certification Body
  • 2.2 Market Segments
    • 2.2.1 Traditional Market Segmentatio
    • 2.2.2 Laboratory Focus and Segmentation
  • 2.3 Industry Structure
    • 2.3.1 Hospital Testing Share
    • 2.3.2 Economies of Scal
    • 2.3.3 Physician Office Lab'
    • 2.3.4 Physician's and POCT

3. Market Trend

  • 3.1 Factors Driving Growth
    • 3.1.1 New Diagnostics Create New Market
    • 3.1.2 New Roles for Diagnostic
    • 3.1.3 Longevity and Outcome
    • 3.1.3 Expanding the Pharmaceutical Toolbo
    • 3.1.4 Regulatory Retreat
  • 3.2 Factors Limiting Growt
    • 3.2.1 Falling Price
    • 3.2.2 Lower Costs
    • 3.2.3 COVID Pandemi
    • 3.2.4 Wellness has a Downsid
  • 3.3 Instrumentation and Automatio
    • 3.3.1 Instruments Key to Market Shar
    • 3.3.2 Bioinformatics Plays a Role
  • 3.4 Diagnostic Technology Developmen
    • 3.4.1 Next Generation Sequencing
    • 3.4.2 Shifting Role of Diagnostic
    • 3.4.3 Multiplexing and Foundation One
    • 3.4.4 Pharmacogenomics Technology
    • 3.4.5 Whole Genome Sequencing
    • 3.4.6 Gene Editing and Gene Therap

4. Molecular Diagnostics Recent Development

  • Recent Developments - Importance and How to Use This Sectio
  • Importance of These Developments
  • How to Use This Section
  • Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform
  • Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
  • Metastatic Cancer Markers Identified in Clinical WGS Stud
  • Stitch Bio Bets on CRISPR Tech
  • Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
  • Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion D
  • Progress, Challenges in Liquid Biopsy Reimbursement
  • Israeli Startup Curesponse Raises $6M
  • Coronavirus Pandemic Bites into European Cancer Researc
  • Veracyte's Prosigna IDs Patients Likely to Benefit from Aggressive Chemotherapy
  • Combining CRISPR and Nanopore Sequencing
  • Liquid Biopsy Detects Cancer Early via Cell Cluster
  • Roche, Illumina unveil 15-year cancer diagnostic tie-up
  • Saga, Servier Sign Liquid Biopsy Services Dea
  • Home urine test could revolutionize diagnosis of prostate cance
  • Cancer Gene Tests Cost-Effective for Breast Cancer Patients
  • Personal Genome Diagnostics Gets CE Mark for Elio Tissue Assay
  • OncoCyte to Buy Cancer Testing Company Razor Genomics
  • Blood Test May Eliminate Need for Exploratory Surger
  • NGS Cancer Panel Receives New York State Conditional Approval
  • Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb

5. Profiles of Key MDx Companies

  • 10x Genomics, Inc
  • Abbott Diagnostics
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medica
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asurage
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, In
  • Biodesix Inc.
  • BioFluidica
  • BioGene
  • Biolidics Lt
  • bioMerieux Diagnostics
  • Bioneer Corporatio
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomic
  • Bristol-Myers Squibb
  • Cancer Genetic
  • Caris Molecular Diagnostics
  • CellMax Lif
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynveni
  • Cytolumina Technologies Corp.
  • CytoTrac
  • Datar Cancer Genetics Limite
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Science
  • Epigenomics A
  • Eurofins Scientific
  • Exosome Diagnostic
  • Exosome Science
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenom
  • FUJIFILM Wako Diagnostics
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivat
  • Integrated Diagnostic
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigm
  • Miltenyi Biotec
  • MIOD
  • miR Scientifi
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyt
  • OncoDN
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologie
  • Panagene
  • Perkin Elme
  • Personal Genome Diagnostics
  • Personali
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SA
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sense Biodetection
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystem
  • simfo GmbH
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostic
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

6. The Global Market for MDx Cancer

  • 6.1 MDx Cancer - Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country

7. Global MDx Cancer Markets - By Type of Cancer

  • 7.1 Global Market by Cancer Type - Overview
    • 7.1.1 Table - Global Market by Cancer Type
    • 7.1.2 Chart - Global Market by Cancer Type - Base/Final Comparison
    • 7.1.3 Chart - Global Market by Cancer Type - Base Year
    • 7.1.4 Chart - Global Market by Cancer Type -Final Year
    • 7.1.5 Chart - Global Market by Cancer Type - Share by Year
    • 7.1.6 Chart - Global Market by Cancer Type - Segment Growth
  • 7.2 MDx Breast Cancer
    • 7.2.1 Table Breast Cancer Testing - by Country
    • 7.2.2 Chart - Breast Cancer Testing Growth
  • 7.3 MDx Colorectal Cance
    • 7.3.1 Table Colorectal Cancer Testing - by Countr
    • 7.3.2 Chart - Colorectal Cancer Testing Growth
  • 7.4 MDx Cervical Cancer
    • 7.4.1 Table Cervical Cancer Testing - by Country
    • 7.4.2 Chart - Cervical Cancer Testing Growt
  • 7.5 MDx Lung Cancer
    • 7.5.1 Table Lung Cancer Testing - by Country
    • 7.5.2 Chart - Lung Cancer Testing Growt
  • 7.6 MDx Prostat
    • 7.2.1 Table Prostate Testing - by Countr
    • 7.6.2 Chart - Prostate Testing Growth
  • 7.7 MDx Melanoma Cancer
    • 7.7.1 Table Melanoma Cancer Testing - by Countr
    • 7.7.2 Chart - Melanoma Cancer Testing Growth
  • 7.8 MDx Blood
    • 7.8.1 Table Blood Testing - by Country
    • 7.8.2 Chart - Blood Testing Growth
  • 7.9 MDx Companion Dx Development
    • 7.9.1 Table Companion Dx Development - by Countr
    • 7.9.2 Chart - Companion Dx Development Growth
  • 7.10 MDx Other Cancer
    • 7.10.1 Table Other Cancer Testing - by Country
    • 7.10.2 Chart - Other Cancer Testing Growth

8. Cancer Treatment and Trials

  • 8.1 FDA Cancer Drug Approvals by Yea
  • 8.2 Clinical Trials Started 2010 to 201
  • 8.3 Prevalence of Cancer Treatments - 2015

Appendices

  • I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule
  • II. FDA Approved Human Genetic Tests
  • III. FDA Approved Microbial Tests
  • III. FDA Approved Pharmacogenomics Tests

Table of Table

  • Table 1 Lab Spending 2014 to 2024
  • Table 2 Market Players by Type
  • Table 3 Clinical Laboratory Departments and Segments
  • Table 4 Laboratory Management Focus - Different Approaches
  • Table 5 Key Segmentation Variables Going Forward
  • Table 6 Five Factors Driving Growth
  • Table 7 Four Factors Limiting Growth
  • Table 8 Key Diagnostic Laboratory Technology Trends
  • Table 9 Next Generation Sequencing Technologies - Speed and Cost
  • Table 10 - Global MDx Cancer Market by Regio
  • Table 11 Global Market by Cancer Type
  • Table 12 MDx Breast Cancer by Country
  • Table 13 MDx Colorectal Cancer by Country
  • Table 14 Cervical Cancer Testing by Country
  • Table 15 Lung Cancer Testing by Country
  • Table 16 Prostate Testing by Countr
  • Table 17 Melanoma Cancer Testing by Country
  • Table 18 MDx Blood by Country
  • Table 19 MDx Companion Dx Development by Country
  • Table 20 MDx Other Cancer Testing by Country
  • Table 21 2020 Clinical Lab Fee Schedule

Table of Figure

  • Figure 1 Clinical Lab Spending 2014 to 2024
  • Figure 2 Growth in Aging Population
  • Figure 3 Death Rates from Cancer - US
  • Figure 4 Comparing MDx Diagnostic and Traditional Testing
  • Figure 5 Global Market Shares Base Yea
  • Figure 6 MDx Market by Cancer - Base vs. Final
  • Figure 7 Cancer Market Base Year
  • Figure 8 Cancer Market Final Yea
  • Figure 9 MDx Cancer Share by Yea
  • Figure 10 MDx Cancer Segment Growth Rates
  • Figure 11 Breast Cancer Testing Growt
  • Figure 12 Colorectal Cancer Testing Growt
  • Figure 13 Cervical Cancer Testing Growt
  • Figure 14 Lung Cancer Testing Growt
  • Figure 15 Prostate Testing Growth
  • Figure 16 Melanoma Cancer Testing Growth
  • Figure 17 Blood Testing Growth
  • Figure 18 Companion Dx Development Growth
  • Figure 19 Other Cancer Testing Growth
  • Figure 20 FDA Cancer Drug Approvals by Yea
  • Figure 21 Clinical Trials for Immunotherapy by Year
  • Figure 22 Pie Chart of Prevalence of Cancer Treatments